Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Spinal Cord Injury
NCT ID: NCT04064957
Last Updated: 2025-09-29
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NO_LONGER_AVAILABLE
Study Classification
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
HBSCI02:
This protocol is part of an FDA Individual Patient Non-emergency Expanded Access Request submitted on behalf of a 38-year-old father and husband who on August 4, 2017 at about 4:30pm, slipped off a boat head-first while in the Florida Keys for a family wedding, and was immediately unable to move his legs. He discharged to Texas via air ambulance for physical rehabilitation on August 23, 2017 with a diagnosis of ASIA B (American Spinal Injury Association) C-5 SCI (spinal cord injury).
HBSCI04:
This Individual Patient Expanded Access IND has been created per the request of a 75-year-old man who has been diagnosed with Spinal Cord Injury. The patient requested this Expanded Access IND with the purpose of possible restoration of nerve transmission and restoring sensation in his upper and lower body using intravenous autologous adipose derived mesenchymal stem cells.
HBSCI05:
This Individual Patient Expanded Access IND has been created per the request of a 26-year-old man who has been diagnosed with Spinal Cord Injury. The patient is a 26-year-old male who suffered an unstable C-6 compressive fracture, crushing the vertebral body and retropulsion of a large bone fragment into the vertebral canal, stenosing 75% of spinal canal in a diving accident on 12/4/2021 in Belize City, Belize. The injury classification is C-6 Asia A injury. The injury left him with flaccid paralysis below the level of C-7 dermatome.
This protocol is part of an FDA Individual Patient Non-emergency Expanded Access Request submitted on behalf of a 38-year-old father and husband who on August 4, 2017 at about 4:30pm, slipped off a boat head-first while in the Florida Keys for a family wedding, and was immediately unable to move his legs. He discharged to Texas via air ambulance for physical rehabilitation on August 23, 2017 with a diagnosis of ASIA B (American Spinal Injury Association) C-5 SCI (spinal cord injury).
HBSCI04:
This Individual Patient Expanded Access IND has been created per the request of a 75-year-old man who has been diagnosed with Spinal Cord Injury. The patient requested this Expanded Access IND with the purpose of possible restoration of nerve transmission and restoring sensation in his upper and lower body using intravenous autologous adipose derived mesenchymal stem cells.
HBSCI05:
This Individual Patient Expanded Access IND has been created per the request of a 26-year-old man who has been diagnosed with Spinal Cord Injury. The patient is a 26-year-old male who suffered an unstable C-6 compressive fracture, crushing the vertebral body and retropulsion of a large bone fragment into the vertebral canal, stenosing 75% of spinal canal in a diving accident on 12/4/2021 in Belize City, Belize. The injury classification is C-6 Asia A injury. The injury left him with flaccid paralysis below the level of C-7 dermatome.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCI
NCT03925649
Spinal Cord Injury at C5-C7 Level
NO_LONGER_AVAILABLE
"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
NCT07238062
Multiple System Atrophy
TEMPORARILY_NOT_AVAILABLE
Intermediate Size Patient Population Expanded Access Protocol to Evaluate HB-adMSCs for the Treatment of Patients With Traumatic or Nontraumatic Brain Injury
NCT07164482
Brain Injury
AVAILABLE
Adipose Stem Cells for Traumatic Spinal Cord Injury
NCT03308565
Spinal Cord Injuries
Paralysis
COMPLETED
PHASE1
Individual Patient Expanded Access IND of Autologous HB-adMSCS for the Treatment of Bilateral Knee Pain.
NCT04604288
Knee Pain Chronic
Osteo Arthritis Knee
NO_LONGER_AVAILABLE
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
HBSCI02:
Once the eligibility is confirmed, approximately 1-3 weeks after the screening/baseline visit, the subject will receive the first infusion. Subsequent treatments will occur every other week in the subject's home, administered by a nurse.
On each of these visits, the subject will receive one autologous HB-adMSC infusion of 200 million (2 x 10\^8 cells) total cells. Every infusion visit will include the following procedures:
1. Interval H\&P and concomitant medications update.
2. QOL and Disability (SCIM self eval) surveys will be completed by the subject with the assistance of the primary caregiver.
3. Vital signs monitoring will be initiated (Heart Rate, BP, Resp., Temp., SpO2).
4. A peripheral IV line will be inserted.
5. A blood sample for clinical labs will be drawn monthly during the infusion period.
6. A "time out" verification of patient/consent/procedure/cell product will be performed.
7. The HB-adMSC infusion will be given by through the peripheral IV.
8. Assessment for Infusion Related AE/SAEs.
9. The subject will be monitored for a minimum of 2 hours.
In-Person Visits The subject will return to the Clinical Trial Network CTN site for In-Person visits to occur at Screening, Baseline and Week twelve (12), twenty-six (26) and at Week fifty-two (52). Week 52 visit will serve as the End of Study visit. The end of study (EOS) visit will include an MRI of the c-spine as well as all of the study procedures for Follow-up Visits without Infusion. A written summary of the results of the treatment, including adverse events will be submitted to the FDA after completion of the last follow-up visit.
Visits without infusion will include:
1. Interval H\&P and concomitant medications update.
2. QOL and Disability (SCIM self eval) surveys will be completed by the subject with the assistance of the primary caregiver.
3. Vital signs monitoring will be initiated (Heart Rate, BP, Resp., Temp., SpO2),
4. A Physical and Neuro Exam (Asia Impairment Scale) will be completed
5. A blood sample for clinical labs (CBC with Platelets, CMP, PT, PTT, TNFa, IL6, CRP) will be drawn.
6. Video documentation of patient condition.
7. Assessment for infusion related AEs/SAEs
8. Weight
HBSCI04:
This expanded access IND was created at the request of the subject who already has his own stem cells banked at Hope Biosciences, LLC. After receiving authorization from FDA and Western IRB, the subject will be contacted and provided with a copy of the informed consent for review. If consent is obtained, the principal investigator or delegated staff will collect patient's medical history and schedule the date for the Infusion 1.
The informed consent process will be documented in the subject's record and will include the discussion points mentioned above. A copy of the signed informed consent will be given to the patient and also placed in the record.
Subject will receive a total of fourteen autologous HB-adMSCs infusion of 200 million cells with a dosing interval of approximately 2 weeks for the first five infusions and 28 days for the remaining 9 infusions over a 44-week period, Laboratory assessments will be collected at Infusion 1, 10, and EOS.
Other assessments should be completed during these visits by the Principal Investigator and/or delegated staff in order to evaluate the safety and efficacy of HB-adMSCs.
1. Collection of Medical History.
2. Collection of Concomitant Medications.
3. Collection of Vital Signs (Respiratory Rate, Blood Pressure, Body Temperature, Heart Rate and Oxygen Saturation). Vital Signs will be collected for 2 hours post investigational product exposure. Every 15 minutes for the first hour and every 30 minutes after that. If it is indicated by principal investigator vital signs should be collected more frequently.
4. EMG NCV is required to be completed at Infusion 1 and EOS. If an EMG NCV has not been done within 28 days of these visits, the Principal Investigator will place an order to obtain it. Any EMG NCV done within 28 days of the visit as standard of care can be used for this requirement.
5. A Physical and Neuro Examination will be completed by the principal investigator.
6. Neuro QOL Scale at Infusion 1, 5, 7, 9, 11 and 13.
7. SCIM (Spinal Cord Independence Measure) Clinician assessment at Infusion 1, 10 and EOS.
8. SCIM (Self-Assessment) at Infusion 1, 10, and EOS.
9. A video documentation of the subject will be recorded during Infusion 1 with the purpose of observing his general physical health, trunk stability and if there are other new changes.
10. Laboratory Samples. A blood sample for clinical labs - CBC with Platelets, CMP, PT, PTT, INR, as well as C-reactive protein and Sedimentation rate to be collected at Infusion 1 and 10 and EOS.
11. Telephone Encounter 24 hours after each infusion to evaluate the incidence of any Adverse event or Serious Adverse Events.
Follow Up Week 48 Phone Call
1. Update medical history and concomitant medications if there is any new information.
2. Assess the incidence of any Adverse event or Serious Adverse Events since last infusion.
End of Study End of Study will include the following study procedures,
1. Interval H\&P and concomitant medications update.
2. Neuro QOL and Disability (SCIM self eval) surveys will be completed by the subject.
3. EMG NCV is required to be completed at this visit. If an EMG NCV has not been done within 28 days of this visit, the Principal Investigator will place an order to obtain it. Any EMG NCV done within 28 days of the visit as standard of care can be used for this requirement.
4. Vital signs monitoring will be initiated (Heart Rate, Blood Pressure, Resp., Temp., SpO2)
5. A Physical and Neuro Examination will be completed by the principal investigator.
6. A blood sample for clinical labs will be collected CBC with Platelets, CMP, PT, PTT, INR, as well as C-reactive protein and Sedimentation rate.
7. A video documentation of the subject will be recorded during this visit with the purpose of observing his general physical health and if there are other new changes.
8. Assess the incidence of any Adverse event or Serious Adverse Events since last infusion.
HBSCI05:
This expanded access IND was created at the request of the subject who already has his own stem cells banked at Hope Biosciences, LLC. After receiving authorization from FDA and Western IRB, the subject will be contacted and provided with a copy of the informed consent for review. The Principal Investigator or delegated staff will contact the patient by telephone and explain the study procedures (including cell infusion, and safety assessment procedures), follow-up visits, potential risks and benefits of the study, alternatives, and the voluntary nature of participation.
Ample time will be given for the patient to ask questions and make a decision about participation. If consent is obtained, the principal investigator or delegated staff will collect patient's medical history and schedule the date for the Infusion 1.
The informed consent process will be documented in the subject's record and will include the discussion points mentioned above. A copy of the signed informed consent will be given to the patient and also placed in the record.
Subject will receive a total of fourteen autologous HB-adMSCs infusion of 200 million cells with a dosing interval of approximately 2 weeks for the first five infusions and 28 days for the remaining 9 infusions over a 44-week period, volume to administer 250 ml of Sodium Chloride 0.9% and infusion rate 4 - 5 ml/min. Laboratory assessments will be collected at Infusion 1, 10, and EOS.
Other assessments should be completed during these visits by the Principal Investigator and/or delegated staff in order to evaluate the safety and efficacy of HB-adMSCs.
1. Collection of Medical History.
2. Collection of Concomitant Medications.
3. Collection of Vital Signs (Respiratory Rate, Blood Pressure, Body Temperature, Heart Rate and Oxygen Saturation). Vital signs will be taken for 1 hour during exposure to the research product with an interval of 15 minutes. However, if warranted or indicated by the investigator vital signs will be taken more frequently or longer if necessary.
4. EMG NCV is required to be completed at Infusion 1 and EOS. If an EMG NCV has not been done within 28 days of these visits, the Principal Investigator will place an order to obtain it. Any EMG NCV done within 28 days of the visit as standard of care can be used for this requirement.
5. A Physical and Neuro Examination will be completed by the principal investigator.
6. Neuro QOL Scale at Infusion 1, 5, 7, 10, 11 and 13, and EOS.
7. SCIM (Spinal Cord Independence Measure) Clinician assessment at Infusion 1, 10 and EOS.
8. SCIM (Self-Assessment) at Infusion 1, 10, and EOS.
9. A video documentation of the subject will be recorded during Infusion 1 with the purpose of observing his general physical health, trunk stability and if there are other new changes.
10. Laboratory Samples. A blood sample for clinical labs - CBC with Platelets, CMP, PT, PTT, INR, as well as C-reactive protein and Sedimentation rate to be collected at Infusion 1 and 10 and EOS.
11. Telephone Encounter 24 hours after each infusion to evaluate the incidence of any Adverse event or Serious Adverse Events.
Follow Up Week 48 Phone Call
1. Update medical history and concomitant medications if there is any new information.
2. Assess the incidence of any Adverse event or Serious Adverse Events since last infusion.
End of Study
End of Study will include the following study procedures,
1. Interval H\&P and concomitant medications update.
2. Neuro QOL and Disability (SCIM self eval) surveys will be completed by the subject.
3. EMG NCV is required to be completed at this visit. If an EMG NCV has not been done within 28 days of this visit, the Principal Investigator will place an order to obtain it. Any EMG NCV done within 28 days of the visit as standard of care can be used for this requirement.
4. Vital signs monitoring will be initiated (Heart Rate, Blood Pressure, Resp., Temp., SpO2)
5. A Physical and Neuro Examination will be completed by the principal investigator.
6. A blood sample for clinical labs will be collected CBC with Platelets, CMP, PT, PTT, INR, as well as C-reactive protein and Sedimentation rate.
7. A video documentation of the subject will be recorded during this visit with the purpose of observing his general physical health and if there are other new changes.
8. Assess the incidence of any Adverse event or Serious Adverse Events since last infusion.
Once the eligibility is confirmed, approximately 1-3 weeks after the screening/baseline visit, the subject will receive the first infusion. Subsequent treatments will occur every other week in the subject's home, administered by a nurse.
On each of these visits, the subject will receive one autologous HB-adMSC infusion of 200 million (2 x 10\^8 cells) total cells. Every infusion visit will include the following procedures:
1. Interval H\&P and concomitant medications update.
2. QOL and Disability (SCIM self eval) surveys will be completed by the subject with the assistance of the primary caregiver.
3. Vital signs monitoring will be initiated (Heart Rate, BP, Resp., Temp., SpO2).
4. A peripheral IV line will be inserted.
5. A blood sample for clinical labs will be drawn monthly during the infusion period.
6. A "time out" verification of patient/consent/procedure/cell product will be performed.
7. The HB-adMSC infusion will be given by through the peripheral IV.
8. Assessment for Infusion Related AE/SAEs.
9. The subject will be monitored for a minimum of 2 hours.
In-Person Visits The subject will return to the Clinical Trial Network CTN site for In-Person visits to occur at Screening, Baseline and Week twelve (12), twenty-six (26) and at Week fifty-two (52). Week 52 visit will serve as the End of Study visit. The end of study (EOS) visit will include an MRI of the c-spine as well as all of the study procedures for Follow-up Visits without Infusion. A written summary of the results of the treatment, including adverse events will be submitted to the FDA after completion of the last follow-up visit.
Visits without infusion will include:
1. Interval H\&P and concomitant medications update.
2. QOL and Disability (SCIM self eval) surveys will be completed by the subject with the assistance of the primary caregiver.
3. Vital signs monitoring will be initiated (Heart Rate, BP, Resp., Temp., SpO2),
4. A Physical and Neuro Exam (Asia Impairment Scale) will be completed
5. A blood sample for clinical labs (CBC with Platelets, CMP, PT, PTT, TNFa, IL6, CRP) will be drawn.
6. Video documentation of patient condition.
7. Assessment for infusion related AEs/SAEs
8. Weight
HBSCI04:
This expanded access IND was created at the request of the subject who already has his own stem cells banked at Hope Biosciences, LLC. After receiving authorization from FDA and Western IRB, the subject will be contacted and provided with a copy of the informed consent for review. If consent is obtained, the principal investigator or delegated staff will collect patient's medical history and schedule the date for the Infusion 1.
The informed consent process will be documented in the subject's record and will include the discussion points mentioned above. A copy of the signed informed consent will be given to the patient and also placed in the record.
Subject will receive a total of fourteen autologous HB-adMSCs infusion of 200 million cells with a dosing interval of approximately 2 weeks for the first five infusions and 28 days for the remaining 9 infusions over a 44-week period, Laboratory assessments will be collected at Infusion 1, 10, and EOS.
Other assessments should be completed during these visits by the Principal Investigator and/or delegated staff in order to evaluate the safety and efficacy of HB-adMSCs.
1. Collection of Medical History.
2. Collection of Concomitant Medications.
3. Collection of Vital Signs (Respiratory Rate, Blood Pressure, Body Temperature, Heart Rate and Oxygen Saturation). Vital Signs will be collected for 2 hours post investigational product exposure. Every 15 minutes for the first hour and every 30 minutes after that. If it is indicated by principal investigator vital signs should be collected more frequently.
4. EMG NCV is required to be completed at Infusion 1 and EOS. If an EMG NCV has not been done within 28 days of these visits, the Principal Investigator will place an order to obtain it. Any EMG NCV done within 28 days of the visit as standard of care can be used for this requirement.
5. A Physical and Neuro Examination will be completed by the principal investigator.
6. Neuro QOL Scale at Infusion 1, 5, 7, 9, 11 and 13.
7. SCIM (Spinal Cord Independence Measure) Clinician assessment at Infusion 1, 10 and EOS.
8. SCIM (Self-Assessment) at Infusion 1, 10, and EOS.
9. A video documentation of the subject will be recorded during Infusion 1 with the purpose of observing his general physical health, trunk stability and if there are other new changes.
10. Laboratory Samples. A blood sample for clinical labs - CBC with Platelets, CMP, PT, PTT, INR, as well as C-reactive protein and Sedimentation rate to be collected at Infusion 1 and 10 and EOS.
11. Telephone Encounter 24 hours after each infusion to evaluate the incidence of any Adverse event or Serious Adverse Events.
Follow Up Week 48 Phone Call
1. Update medical history and concomitant medications if there is any new information.
2. Assess the incidence of any Adverse event or Serious Adverse Events since last infusion.
End of Study End of Study will include the following study procedures,
1. Interval H\&P and concomitant medications update.
2. Neuro QOL and Disability (SCIM self eval) surveys will be completed by the subject.
3. EMG NCV is required to be completed at this visit. If an EMG NCV has not been done within 28 days of this visit, the Principal Investigator will place an order to obtain it. Any EMG NCV done within 28 days of the visit as standard of care can be used for this requirement.
4. Vital signs monitoring will be initiated (Heart Rate, Blood Pressure, Resp., Temp., SpO2)
5. A Physical and Neuro Examination will be completed by the principal investigator.
6. A blood sample for clinical labs will be collected CBC with Platelets, CMP, PT, PTT, INR, as well as C-reactive protein and Sedimentation rate.
7. A video documentation of the subject will be recorded during this visit with the purpose of observing his general physical health and if there are other new changes.
8. Assess the incidence of any Adverse event or Serious Adverse Events since last infusion.
HBSCI05:
This expanded access IND was created at the request of the subject who already has his own stem cells banked at Hope Biosciences, LLC. After receiving authorization from FDA and Western IRB, the subject will be contacted and provided with a copy of the informed consent for review. The Principal Investigator or delegated staff will contact the patient by telephone and explain the study procedures (including cell infusion, and safety assessment procedures), follow-up visits, potential risks and benefits of the study, alternatives, and the voluntary nature of participation.
Ample time will be given for the patient to ask questions and make a decision about participation. If consent is obtained, the principal investigator or delegated staff will collect patient's medical history and schedule the date for the Infusion 1.
The informed consent process will be documented in the subject's record and will include the discussion points mentioned above. A copy of the signed informed consent will be given to the patient and also placed in the record.
Subject will receive a total of fourteen autologous HB-adMSCs infusion of 200 million cells with a dosing interval of approximately 2 weeks for the first five infusions and 28 days for the remaining 9 infusions over a 44-week period, volume to administer 250 ml of Sodium Chloride 0.9% and infusion rate 4 - 5 ml/min. Laboratory assessments will be collected at Infusion 1, 10, and EOS.
Other assessments should be completed during these visits by the Principal Investigator and/or delegated staff in order to evaluate the safety and efficacy of HB-adMSCs.
1. Collection of Medical History.
2. Collection of Concomitant Medications.
3. Collection of Vital Signs (Respiratory Rate, Blood Pressure, Body Temperature, Heart Rate and Oxygen Saturation). Vital signs will be taken for 1 hour during exposure to the research product with an interval of 15 minutes. However, if warranted or indicated by the investigator vital signs will be taken more frequently or longer if necessary.
4. EMG NCV is required to be completed at Infusion 1 and EOS. If an EMG NCV has not been done within 28 days of these visits, the Principal Investigator will place an order to obtain it. Any EMG NCV done within 28 days of the visit as standard of care can be used for this requirement.
5. A Physical and Neuro Examination will be completed by the principal investigator.
6. Neuro QOL Scale at Infusion 1, 5, 7, 10, 11 and 13, and EOS.
7. SCIM (Spinal Cord Independence Measure) Clinician assessment at Infusion 1, 10 and EOS.
8. SCIM (Self-Assessment) at Infusion 1, 10, and EOS.
9. A video documentation of the subject will be recorded during Infusion 1 with the purpose of observing his general physical health, trunk stability and if there are other new changes.
10. Laboratory Samples. A blood sample for clinical labs - CBC with Platelets, CMP, PT, PTT, INR, as well as C-reactive protein and Sedimentation rate to be collected at Infusion 1 and 10 and EOS.
11. Telephone Encounter 24 hours after each infusion to evaluate the incidence of any Adverse event or Serious Adverse Events.
Follow Up Week 48 Phone Call
1. Update medical history and concomitant medications if there is any new information.
2. Assess the incidence of any Adverse event or Serious Adverse Events since last infusion.
End of Study
End of Study will include the following study procedures,
1. Interval H\&P and concomitant medications update.
2. Neuro QOL and Disability (SCIM self eval) surveys will be completed by the subject.
3. EMG NCV is required to be completed at this visit. If an EMG NCV has not been done within 28 days of this visit, the Principal Investigator will place an order to obtain it. Any EMG NCV done within 28 days of the visit as standard of care can be used for this requirement.
4. Vital signs monitoring will be initiated (Heart Rate, Blood Pressure, Resp., Temp., SpO2)
5. A Physical and Neuro Examination will be completed by the principal investigator.
6. A blood sample for clinical labs will be collected CBC with Platelets, CMP, PT, PTT, INR, as well as C-reactive protein and Sedimentation rate.
7. A video documentation of the subject will be recorded during this visit with the purpose of observing his general physical health and if there are other new changes.
8. Assess the incidence of any Adverse event or Serious Adverse Events since last infusion.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Spinal Cord Injuries
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HB-adMSCs
Intervention Type
BIOLOGICAL
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Hope Biosciences autologous adipose-derived mesenchymal stem cells
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Adult individual 18 yr. of age or older.
2. Cognitively intact and capable of giving informed consent.
3. Clinical diagnosis of a non-penetrating traumatic SCI to the cervical spine
4. Patient and Caregiver agree to use Care Connect app or web version of VirTrial platform for virtual visits.
1. Adult individual 18 years of age or older.
2. Cognitively intact and capable of giving informed consent.
3. Clinical diagnosis of Spinal Cord Injury.
4. Subject has mesenchymal stem cells banked at Hope Biosciences.
5. The patient accepts to receive treatment and to comply with follow-up visits.
1. Adult individual 18 years of age or older.
2. Cognitively intact and capable of giving informed consent.
3. Clinical diagnosis of Spinal Cord Injury.
4. Subject has mesenchymal stem cells banked at Hope Biosciences.
5. The patient accepts to receive treatment and to comply with follow-up visits.
2. Cognitively intact and capable of giving informed consent.
3. Clinical diagnosis of a non-penetrating traumatic SCI to the cervical spine
4. Patient and Caregiver agree to use Care Connect app or web version of VirTrial platform for virtual visits.
1. Adult individual 18 years of age or older.
2. Cognitively intact and capable of giving informed consent.
3. Clinical diagnosis of Spinal Cord Injury.
4. Subject has mesenchymal stem cells banked at Hope Biosciences.
5. The patient accepts to receive treatment and to comply with follow-up visits.
1. Adult individual 18 years of age or older.
2. Cognitively intact and capable of giving informed consent.
3. Clinical diagnosis of Spinal Cord Injury.
4. Subject has mesenchymal stem cells banked at Hope Biosciences.
5. The patient accepts to receive treatment and to comply with follow-up visits.
Exclusion Criteria
1. Prior history of:
1. Recent or ongoing infection,
2. Clinically significant cardiovascular, lung, renal, hepatic, or endocrine disease,
3. Neurodegenerative disorders,
4. Cancer,
5. Immunosuppression as defined by WBC \< 3, 000 cells/ml at baseline screening,
6. Chemical or ETOH dependency,
2. Having a contraindication to MRI scans
3. Other acute or chronic medical conditions that, in the opinion of the investigator, may increase the risks associated with study participation or HB-adMSC administration
4. Participation in other interventional research studies.
5. Unwillingness to return for follow-up visits
HBSCI04:
1. Clinically significant, uncontrolled cardiovascular, lung, renal, hepatic, or endocrine disease or any other acute or chronic medical condition that, in the opinion of the investigator may increase the risks associated with study participation.
2. Active Alcohol or Drug addiction.
3. Participation in concurrent interventional research studies during this study.
4. Severe organ failure (heart, kidney or liver) confirmed by additional tests or medical history.
5. Unwillingness to return for follow-up visits.
HBSCI05:
1. Clinically significant, uncontrolled cardiovascular, lung, renal, hepatic, or endocrine disease or any other acute or chronic medical condition that, in the opinion of the investigator may increase the risks associated with study participation.
2. Active Alcohol or Drug addiction.
3. Participation in concurrent interventional research studies during this study.
4. Severe organ failure (heart, kidney or liver) confirmed by additional tests or medical history.
5. Unwillingness to return for follow-up visits.
1. Recent or ongoing infection,
2. Clinically significant cardiovascular, lung, renal, hepatic, or endocrine disease,
3. Neurodegenerative disorders,
4. Cancer,
5. Immunosuppression as defined by WBC \< 3, 000 cells/ml at baseline screening,
6. Chemical or ETOH dependency,
2. Having a contraindication to MRI scans
3. Other acute or chronic medical conditions that, in the opinion of the investigator, may increase the risks associated with study participation or HB-adMSC administration
4. Participation in other interventional research studies.
5. Unwillingness to return for follow-up visits
HBSCI04:
1. Clinically significant, uncontrolled cardiovascular, lung, renal, hepatic, or endocrine disease or any other acute or chronic medical condition that, in the opinion of the investigator may increase the risks associated with study participation.
2. Active Alcohol or Drug addiction.
3. Participation in concurrent interventional research studies during this study.
4. Severe organ failure (heart, kidney or liver) confirmed by additional tests or medical history.
5. Unwillingness to return for follow-up visits.
HBSCI05:
1. Clinically significant, uncontrolled cardiovascular, lung, renal, hepatic, or endocrine disease or any other acute or chronic medical condition that, in the opinion of the investigator may increase the risks associated with study participation.
2. Active Alcohol or Drug addiction.
3. Participation in concurrent interventional research studies during this study.
4. Severe organ failure (heart, kidney or liver) confirmed by additional tests or medical history.
5. Unwillingness to return for follow-up visits.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hope Biosciences Research Foundation
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Djamchid Lotfi, MD
Role: PRINCIPAL_INVESTIGATOR
Hope Biosciences Stem Cell Research Foundation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hope Biosciences Stem Cell Research Foundation
Sugar Land, Texas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Related Links
Access external resources that provide additional context or updates about the study.
http://www.hope.bio
Hope Biosciences
https://www.hopebio.org/
Hope Biosciences Stem Cell Research Foundation
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HBSCI02, HBSCI04, HBSCI05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy
NCT04063215
COMPLETED
PHASE1/PHASE2
Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury
NCT02237547
WITHDRAWN
PHASE1/PHASE2
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
NCT05951777
RECRUITING
PHASE2
Transplantation of Autologous Bone Marrow or Leukapheresis-Derived Stem Cells for Treatment of Spinal Cord Injury
NCT02687672
UNKNOWN
PHASE2
Treatment for Acute Spinal Cord Injury
NCT00695149
TERMINATED
PHASE1/PHASE2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
NCT04476901
RECRUITING
PHASE2
Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome
NCT03818854
COMPLETED
PHASE2
Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome
NCT01775774
COMPLETED
PHASE1
Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury
NCT06654193
RECRUITING
PHASE1/PHASE2
Expanded Access Multi-Patient Experimental Treatment Involving Allogeneic Human Mesenchymal Stem Cells (hMSCs) in Subjects With Acute Ischemic Stroke (EXPAND)
NCT05522569
TEMPORARILY_NOT_AVAILABLE
Safety Study and Preliminary Efficacy of Infusion Haploidentical Mesenchymal Stem Cells Derived From Bone Marrow for Treating Recessive Dystrophic Epidermolysis Bullosa
NCT04153630
UNKNOWN
PHASE1/PHASE2
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for TBI
NCT05018832
NOT_YET_RECRUITING
PHASE1
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)
NCT01770613
WITHDRAWN
PHASE2
Effect of Mesenchymal Stem Cells(MSCs) Transplantation for Acute Cerebral Infarction Patients
NCT04093336
UNKNOWN
PHASE1/PHASE2
Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies
NCT02804945
COMPLETED
PHASE1
Autologous Mesenchymal Stem Cells Transplantation in Thoracolumbar Chronic and Complete Spinal Cord Injury Spinal Cord Injury
NCT02574585
UNKNOWN
PHASE2
Safety and Effectiveness of Banked Cord Blood or Bone Marrow Stem Cells in Children With Cerebral Palsy (CP).
NCT01988584
COMPLETED
PHASE2
Manufacturing of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells for Treatment of Severe Systemic Sclerosis
NCT05947682
UNKNOWN
NA
Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19
NCT04362189
TERMINATED
PHASE2
hUC Mesenchymal Stem Cells (19#iSCLife®-CSD) Therapy for Patients With Healing Poor After Uterus Injury
NCT03386708
COMPLETED
PHASE1
Safety/Feasibility of Autologous Mononuclear Bone Marrow Cells in Stroke Patients
NCT00859014
COMPLETED
PHASE1
Safety Study of Bone Marrow Derived Cells to Treat Damaged Heart Muscle
NCT00361855
COMPLETED
PHASE1
AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial
NCT05491681
WITHDRAWN
PHASE1
Autologous Bone Marrow-derived Mononuclear Cells for Acute Spinal Cord Injury
NCT04528550
UNKNOWN
PHASE2
Autologous Implantation of Mesenchymal Stem Cells for the Treatment of Distal Tibial Fractures
NCT00250302
COMPLETED
PHASE1/PHASE2